Endoscopy 2018; 50(04): S57
DOI: 10.1055/s-0038-1637196
ESGE Days 2018 oral presentations
20.04.2018 – Bariatric endoscopy
Georg Thieme Verlag KG Stuttgart · New York

ENDOSCOPIC SLEEVE GASTROPLASTY IS SAFE AND EFFECTIVE IN MORBID OBESITY

I Boškoski
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
V Bove
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
R Landi
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
F Mangiola
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
L Laterza
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
G Gibiino
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
A Tringali
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
P Familiari
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
V Perri
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
,
G Costamagna
1   Catholic University of Rome, Digestive Endoscopy Unit, Rome, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2018 (online)

Also available at
 

Aims:

Obesity has a high impact on the development of the most prevalent chronic conditions (cardiovascular disease, type-II diabetes, etc.). Endoscopic sleeve gastroplasty (ESG) is a new endoscopic technique for the treatment of morbid obesity.

Methods:

Patients with BMI> 35 treated at our centre were retrospectively identified. ESG was performed with Overstitch (Apollo-Endosurgery), a full-thickness endoscopic suturing device. The stitches are placed between the anterior gastric wall, the great curvature and the posterior gastric wall, in order to substantially reduce the gastric volume. Telephonic follow-up was done at 1, 3, 6 and 12 months. The quality of life was evaluated according to the Quality Of Life Scale (QOLS).

Results:

Twelve patients (8 female, mean-age 49.6 years) underwent ESG from May-2016 to June-2017. Indications of ESG was discussed by a multidisciplinary panel. Baseline mean BMI was 41.5 (range 35 – 45.7) and mean weight was 117 kg (range 95 – 149). Mean procedure time was 61.6 minutes (range 30 – 92) and a mean number of 5.4 stitches per-patient were placed (range 3 – 8). After suturing the patency of the gastric outlet was tested with a standard gastroscope. There were no complications.

Eleven patients completed the follow-up at 1, 3 and 6 months and 3 cases already reached the 12 months follow-up. One-patient was lost at follow-up. One patient regained weight. Mean weight loss at 6-month in 10 patients was 16 Kg (14.4% of initial weight).

All the patients reported satiety after 1-month, which was confirmed by 72.3% (n = 8/11) after 6-months. In addition, 72.7% (n = 8/11) had an improvement quality-of-life in terms of physical activity, relationships and dietary habits.

Conclusions:

In our experience ESG was a safe and effective procedure, with promising results in the medium-term follow-up.

ESG may improve patients’ quality of life.

Further clinical trials are needed to establish the role of ESG in the multidisciplinary therapeutic strategy of morbid obesity.